Valproate as an adjunct to antipsychotics for schizophrenia: A systematic review of randomized trials

Anja Basan; Werner Kissling; Stefan Leucht

doi:10.1016/j.schres.2004.01.016

Valproate as an adjunct to antipsychotics for schizophrenia: A systematic review of randomized trials

Anja Basan, Werner Kissling, Stefan Leucht

Department of Psychiatry and Psychotherapy

Research output: Contribution to journal › Article › peer-review

57 Scopus citations

Abstract

Randomized controlled trials comparing valproate (as a sole, or as an adjunctive compound) to placebo for patients with schizophrenia or schizophrenia-like disorders were summarized in a metaanalysis. It was possible to include only five trials (n=379) examining valproate as add-on to antipsychotics in this review. Some of the single studies showed inconsistent beneficial effects on some aspects of response, but no overall superiority of valproate augmentation at study endpoints was shown.

Original language	English
Pages (from-to)	33-37
Number of pages	5
Journal	Schizophrenia Research
Volume	70
Issue number	1
DOIs	https://doi.org/10.1016/j.schres.2004.01.016
State	Published - 1 Sep 2004

Keywords

Add-on treatment
Metaanalysis
Schizophrenia
Valproate
Valproid acid

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.schres.2004.01.016

Cite this

@article{d51fb377264d47cb858f00f4c6432f0f,

title = "Valproate as an adjunct to antipsychotics for schizophrenia: A systematic review of randomized trials",

abstract = "Randomized controlled trials comparing valproate (as a sole, or as an adjunctive compound) to placebo for patients with schizophrenia or schizophrenia-like disorders were summarized in a metaanalysis. It was possible to include only five trials (n=379) examining valproate as add-on to antipsychotics in this review. Some of the single studies showed inconsistent beneficial effects on some aspects of response, but no overall superiority of valproate augmentation at study endpoints was shown.",

keywords = "Add-on treatment, Metaanalysis, Schizophrenia, Valproate, Valproid acid",

author = "Anja Basan and Werner Kissling and Stefan Leucht",

note = "Funding Information: The authors wish to thank the editorial team of the Cochrane schizophrenia group, under the auspices of which the review was undertaken (Basan et al., 2003) . The work is part of the German Research Network on Schizophrenia and was funded by the German Federal Ministry for Education and Research BMBF (grant 01 GI 993x).",

year = "2004",

month = sep,

day = "1",

doi = "10.1016/j.schres.2004.01.016",

language = "English",

volume = "70",

pages = "33--37",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Valproate as an adjunct to antipsychotics for schizophrenia

T2 - A systematic review of randomized trials

AU - Basan, Anja

AU - Kissling, Werner

AU - Leucht, Stefan

N1 - Funding Information: The authors wish to thank the editorial team of the Cochrane schizophrenia group, under the auspices of which the review was undertaken (Basan et al., 2003) . The work is part of the German Research Network on Schizophrenia and was funded by the German Federal Ministry for Education and Research BMBF (grant 01 GI 993x).

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Randomized controlled trials comparing valproate (as a sole, or as an adjunctive compound) to placebo for patients with schizophrenia or schizophrenia-like disorders were summarized in a metaanalysis. It was possible to include only five trials (n=379) examining valproate as add-on to antipsychotics in this review. Some of the single studies showed inconsistent beneficial effects on some aspects of response, but no overall superiority of valproate augmentation at study endpoints was shown.

AB - Randomized controlled trials comparing valproate (as a sole, or as an adjunctive compound) to placebo for patients with schizophrenia or schizophrenia-like disorders were summarized in a metaanalysis. It was possible to include only five trials (n=379) examining valproate as add-on to antipsychotics in this review. Some of the single studies showed inconsistent beneficial effects on some aspects of response, but no overall superiority of valproate augmentation at study endpoints was shown.

KW - Add-on treatment

KW - Metaanalysis

KW - Schizophrenia

KW - Valproate

KW - Valproid acid

UR - http://www.scopus.com/inward/record.url?scp=3142713738&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2004.01.016

DO - 10.1016/j.schres.2004.01.016

M3 - Article

C2 - 15246461

AN - SCOPUS:3142713738

SN - 0920-9964

VL - 70

SP - 33

EP - 37

JO - Schizophrenia Research

JF - Schizophrenia Research

IS - 1

ER -

Valproate as an adjunct to antipsychotics for schizophrenia: A systematic review of randomized trials

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this